Circulating angiopoietic cells and diabetic retinopathy in Type 2 diabetes mellitus, with or without macrovascular disease

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4655-4662

  Brunner, Simon ^a,b   Hoellerl, Florian ^c   Schmid Kubista, Katharina E ^a,b   Zeiler, Florian ^a,b   Schernthaner, Guntram ^a   Binder, Susanne ^a,b   Schernthaner, Gerit Holger ^c  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b Ludwig Boltztmann Institute for Retinology and Biomicroscopic Laser Surgery   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; FLUORESCENCE ANGIOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIC DISK; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; SMOKING; STROKE; CELL COUNT; COMPARATIVE STUDY; CYTOLOGY; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY;

AGED; CASE-CONTROL STUDIES; CELL COUNT; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; FLOW CYTOMETRY; FLUORESCEIN ANGIOGRAPHY; HEMATOPOIETIC STEM CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MICROVESSELS; MIDDLE AGED; SMOKING;

EID: 80051600164     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6520     Document Type: Article

References (44)

1. Fong DS, Aiello LP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540-2553.
2. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152(1):27-30.
3. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening and novel therapies. Diabetes Care. 2003;26(9):2653-2664.
4. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: ETDRS Report Number 18. Invest Ophthalmol Vis Sci. 1998;39(2):233-252.
5. Foster A, Resnikoff S. The impact of Vision 2020 on global blindness. Eye. 2005;19(10):1133-1135.
6. Antonetti DA, Barber AJ, Bronson SK, et al. and the JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55(9):2401-2411.
7. Steiner G. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD. Cardiovasc Drugs Ther. 2009;23(5):403-408. Review.
8. Turnbull FM, Abraira C, Anderson RJ, et al. Glucose control modestly reduces risk for MVD: intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11): 2288-2298.
9. Nguyen TT, Wong TY. Retinal arteriolar but not venous narrowing is associated with risk for MVD: retinal vascular changes and diabetic retinopathy. Curr Diab Rep. 2009;9(4):277-283.
10. Otani A, Friedlander M. Retinal vascular regeneration. Semin Ophthalmol. 2005;20(1):43-50.
11. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22(1):36-52.
12. Clermont AC, Aiello LP, Mori F, et al. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol. 1997;124(4):433-446.
13. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 2000;86(12):1198-1202.
14. Shao H, Tan Y, Eton D, et al. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells. 2008;26(5):1376-1384.
15. Cubbon RM, Kahn MB, Wheatcroft SB. Effects of insulin resistance on endothelial progenitor cells and vascular repair (review). Clin Sci (Lond). 2009;3:117(5):173-190.
16. Müller P, Kazakov A, Jagoda P, et al. ACE inhibition promotes upper regulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res. 2009;1:83(1): 106-114.
17. Michaud SE, Dussault S, Haddad P, et al. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis. 2006;187(2):423-432. 2009 Oct;23(5): 403-408. Review.
18. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85(3):221-228.
19. Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye. 2006;20(5):546-552.
20. Fadini GP, Sartore S, Baesso I, et al. Endothelial progenitor cells and the diabetic paradox. Diabetes Care. 2006;29(3):714-716.
21. Early Treatment Diabetic Retinopathy Study Research Group. ETDRS Study: design and baseline patient characteristics. ETDRS Report Number 7. Ophthalmology. 1991;98(5 suppl):741-756.
22. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report Number 12. Ophthalmology. 1991;98(5 suppl): 823-833.
23. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from fundus photographs: an extension of the modified Airlie House classification. ETDRS Report Number 10. Ophthalmology. 1991;98(5 suppl):786-806.
24. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Helsinki, Finland. 1964; amended in Tokyo, Japan. 1975; Venice, Italy. 1983; Hong Kong 1989; Somerset West, South Africa. 1996; Edinburgh, Scotland. 2000; Washington, USA., 2002; Tokyo, Japan 2004. Available at http://www.wma.net/en/60about/ 70history/01declarationHelsinki/index.html. Accessed August 10, 2010.
25. ICH Harmonised Tripartite Guideline for Good Clinical Practice. available at http://www.fda.gov/oc/gcp/guidance.html. Accessed August 10, 2010.
26. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities L/21/34 1.5.2001 and the EudraCT Supporting Documentation updated 04/08/05. Available at http:// ec.europa.eu/health/documents/eudralex/vol-10/. Accessed August 10, 2010.
27. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302): 964-967.
28. Gehling UM, Ergün S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000;95(10):3106-3112.
29. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952-958.
30. Blann AD, Pretorius A. Circulating endothelial cells and endothelial progenitor cells: two sides of the same coin, or two different coins? Atherosclerosis. 2006;188:12-18.
31. Stevens T, Rosenberg R, Aird W, et al. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am J Physiol Cell Physiol. 2001;281:C1422-C1433.
32. Sutherland DR, Anderson L, Keeney M, Nayar Chin-Yee I. The ISHAGE guidelines for CD34/ cell determination by flow cytometry. J Hematother. 1996;5:213.
33. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89(7):2233-2258.
34. Barnett D, Janossy G, Lubenko A, Matutes E, Newland A, Reilly JT. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells; prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol. 1999;21(5):301-308.
35. Brunner S, Schernthaner GH, Satler M, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data Invest. Ophthalmol Vis Sci. 2009; 50(1):392-398.
36. Garner A. Histopathology of diabetic retinopathy in man. Eye. 1993;7:250-253.
37. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45:1449-1457.
38. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care. 2007;30:292-299.
39. Busik JV, Tikhonenko M, Bhatwadekar A, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med. 2009;206:2897-2906.
40. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
41. Humpert PM, Neuwirth R, Battista MJ, et al. SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes. Diabetes Care. 2005;28(4):934-936.
42. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008;28:1584-1595.
43. ACCORD Study Group, Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-244.
44. Keech AC, Mitchell P, Summanen PA, et al. FIELD study investigators; effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007;17:370:1687-1697.